LMR Partners LLP purchased a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 24,167 shares of the biotechnology company's stock, valued at approximately $3,597,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGEN. Andra AP fonden purchased a new position in shares of Repligen during the 2nd quarter valued at $25,000. International Assets Investment Management LLC acquired a new position in Repligen in the 2nd quarter worth about $33,000. UMB Bank n.a. raised its stake in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock valued at $36,000 after buying an additional 136 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after buying an additional 127 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Insider Buying and Selling
In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company's stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is owned by company insiders.
Analysts Set New Price Targets
A number of research firms have issued reports on RGEN. Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a report on Wednesday, November 13th. Stephens reissued an "overweight" rating and set a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Repligen presently has a consensus rating of "Moderate Buy" and an average price target of $190.25.
View Our Latest Research Report on RGEN
Repligen Stock Performance
Shares of Repligen stock traded up $5.08 during midday trading on Tuesday, hitting $128.49. The company had a trading volume of 963,091 shares, compared to its average volume of 668,961. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The business's 50 day simple moving average is $140.67 and its two-hundred day simple moving average is $143.94. The stock has a market cap of $7.20 billion, a PE ratio of -347.26, a P/E/G ratio of 3.75 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the previous year, the firm posted $0.23 EPS. The business's revenue was up 9.7% compared to the same quarter last year. As a group, equities analysts predict that Repligen Co. will post 1.52 EPS for the current fiscal year.
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
